Stock Financial Ratios, Dividends, Split History

WLH / Lyon William Homes financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price24.47
Volume244,600.00
Market Cap ($M)803.83
Enterprise Value ($M)2,127.07
Book Value ($M)782.28
Book Value / Share23.56
Price / Book1.03
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 4,817,394
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 37,040,137
Common Shares Outstanding 34,267,510
Weighted Average Number Of Diluted Shares Outstanding 38,663,667
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.03
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Assets2,626.41
Liabilities1,772.75
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Management Fees Revenue0.00
Sales Revenue Services Net0.00
Home Building Revenue1,795,074,000.00
Construction Revenue1,454,000.00
Revenues1,796,528,000.00
Operating Income137.96
Net Income57.75
Earnings Per Share Diluted1.24
Earnings Per Share Basic1.30
Cash Flow Statement (mra) ($M)
Cash From Operations167.45
Cash from Investing-4.30
Cash from Financing-4.30
Identifiers and Descriptors
CUSIP552074700
Central Index Key (CIK)1095996
Related CUSIPS
552074882

Split History

Stock splits are used by Lyon William Homes to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

Related News Stories

The Zacks Analyst Blog Highlights: Kforce, Burlington Stores, Brookline Bancorp, Federated National Holding and Salem Media Group

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Kforce Inc. (KFRC - Free Report) , Burlington Stores, Inc. (BURL - Free Report) , Brookline Bancorp, Inc. (BRKL - Free Report) , Federated National Holding Company (FNHC - Free Report) and Salem Media Group, Inc. (55-0)

Anadarko Petroleum, Symantec and Palo Alto Networks highlighted as Zacks Bull and Bear of the Day

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks Equity Research highlights Anadarko Petroleum (APC - Free Report) as the Bull of the Day, Symantec (SYMC - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Palo Alto Networks (PANW - Free Report) . (85-0)

The Zacks Analyst Blog Highlights: Visa, Medtronic, Salesforce, Dollar General and Martin Marietta

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Visa (V - Free Report) , Medtronic (MDT - Free Report) , Salesforce CRM, Dollar General (DG - Free Report) and Martin Marietta (MLM - Free Report) . (49-0)

The Zacks Analyst Blog Highlights: Zebra Technologies, Anhui Conch Cement and Graco

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Zebra Technologies (ZBRA - Free Report) , Anhui Conch Cement (AHCHY - Free Report) and Graco (GGG - Free Report) . (48-0)

Zacks Industry Outlook Highlights: Lennar, M/I Homes and William Lyon Homes

2018-06-04 zacks
Chicago, IL – June 4, 2018 – Today, Zacks Equity Research discusses the Industry: Housing, Part 2, including Lennar (LEN - Free Report) , M/I Homes, Inc. (MHO - Free Report) and William Lyon Homes (WLH - Free Report) . (52-0)

CUSIP: 552074700